Partnerships

It has been our distinct honor and pleasure at Nina Capital to be one of Terapet’s earliest backers and a key supporter since their seed stage in 2020. Terapet is a truly innovative company bringing breakthrough solutions to proton therapy and nuclear imaging. Born as a CERN spinoff, Terapet's proprietary platform technology represents a leap forward, leveraging advanced physics to provide high-resolution imaging capabilities that make cancer treatment safer and more precise. The team, led by Dr. Christina Vallgren, is exceptional, combining deep scientific and clinical expertise with operational excellence. It has been fascinating to witness Terapet’s evolution from an early-stage venture to a mature organization with proven industrial and clinical validation. Their recent milestones, including successful first-in-human scanning and benchmarking against the world's leading systems, confirm our long-held belief: Terapet’s technology is superior. Looking ahead, Terapet has a clear long-term vision and immense scalability potential. Their innovative model and the introduction of the Nuclyscan total-body PET scanner are poised to disrupt the market and democratize access to personalized precision medicine globally. Whoever partners with Terapet now is securing its leading place in the market for the next two decades. Terapet is not just building a product; they are building the future of cancer care.

Collaborating with TERAPET is a very positive experience from both a scientific and technical standpoint. The interaction between our teams is efficient and well aligned, supporting the development and evaluation of advanced PET-based verification approaches in particle therapy.   Within ongoing initiatives such as FLASHVIVO, this collaboration contributes to exploring new strategies for in-beam verification and biological guidance under challenging irradiation conditions. TERAPET demonstrates strong technical expertise and a clear understanding of clinical and research needs, making them a reliable and forward-looking partner in this field.

Terapet combines deeptech innovation with exceptional execution to translate breakthrough science into real-world impact.

Working with TERAPET is proving to be a constructive collaboration, particularly in the context of developing and testing innovative concepts for PET-based verification in particle therapy.   The collaboration supports experimental activities related to synchronization, motion-resolved imaging, and feasibility studies, included within the framework of the FLASHVIVO project. TERAPET brings strong technical competence, flexibility, and responsiveness, enabling efficient progress in complex research environments and contributing to the advancement of in-beam verification techniques.

Our collaboration with TERAPET has opened interesting perspectives for the use of PET-based technologies in particle therapy, particularly in treatment verification and future adaptive approaches. While these insights are currently based on research and ongoing evaluations rather than routine clinical implementation, they provide a strong foundation for future clinical translation. We particularly value TERAPET’s ability to translate advanced detector and imaging concepts into solutions with real potential for integration into clinical workflows. The collaboration has been highly constructive, and we see promising opportunities to improve treatment accuracy and patient-specific optimization in proton and ion therapy